Table of Contents: 1 Report Prologue 2 Market Introduction 2.1 Definition 2.2 Scope of Study 2.3 Research Objective 2.4 Assumptions & Limitations 2.4.1 Assumptions 2.4.2 Limitations 2.5 Market Structure 3 Research Methodology 3.1.1 Primary Research Methodology 3.1.2 Secondary Research Methodology 3.1.3 Market Share Analysis 3.1.4 Market Pricing Approach 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Increasing prevalence of diabetes and atherosclerosis (Impact Weightage 40%) 4.2.2 Change in lifestyle (Impact Weightage 35%) 4.2.3 Increasing prevalence of glaucoma, lymphoma, and multiple myeloma (Impact Weightage 25%) 4.3 Restraints 4.3.1 Side effect of treatment (Impact Weightage 60%) 4.3.2 High cost of treatment (Impact Weightage 40%) 5 Market Factor Analysis 5.1 Porters Five Forces Model 5.1.1 Bargaining Power of Suppliers 5.1.2 Bargaining Power of Buyers 5.1.3 Threat of New Entrants 5.1.4 Threat of Substitutes 5.1.5 Intensity of Rivalry 5.2 Value Chain Analysis 5.2.1 R&D 5.2.2 Manufacturing 5.2.3 Distribution & Sales 5.2.4 Post-sales Monitoring 5.3 Demand & Supply: Gap Analysis 5.4 Pricing Analysis 5.5 Investment Opportunity Analysis 6 Global Retinal Vein Occlusion Market, By Type 6.1 Branch Retinal Artery Occlusion 6.2 Central Retinal Vein Occlusion 7 Global Retinal Vein Occlusion Market, By Condition 7.1 Non-Ischemic 7.2 Ischemic 8 Global Retinal Vein Occlusion Market, By Diagnosis 8.1 Optical Coherence Tomography 8.2 Fundoscopic Examination 8.3 Fluorescein Angiography 9 Global Retinal Vein Occlusion Market, By Treatment 9.1 Antivascular Endothelial Growth Factor 9.1.1 Aflibercept 9.1.2 Ranibizumab 9.2 Corticosteroid Drugs 9.2.1 Triamcinolone Acetonide 9.2.2 Dexamethasone 9.3 Laser Retinal Photocoagulation 10 Global Retinal Vein Occlusion Market, By End User 10.1 Hospitals and Clinics 10.2 Research & Academics Centers 11 Global Retinal Vein Occlusion Market, By Region 11.1 Americas 11.1.1 North America 11.1.1.1 U. S. 11.1.1.2 Canada 11.1.2 South America 11.2 Europe 11.2.1 Western Europe 11.2.1.1 Germany 11.2.1.2 France 11.2.1.3 U.K 11.2.1.4 Italy 11.2.1.5 Spain 11.2.1.6 Rest of Western Europe 11.2.2 Eastern Europe 11.3 Asia Pacific 11.3.1 Japan 11.3.2 China 11.3.3 India 11.3.4 Australia 11.3.5 Republic of Korea 11.3.6 Rest of Asia Pacific 11.4 Middle East & Africa 11.4.1 Africa 12 Competitive Landscape 12.1 Introduction 12.2 Company Share Analysis 13 Company Profiles 13.1 Allergan Plc 13.1.1 Company Overview 13.1.2 Financials 13.1.3 Products 13.1.4 Strategy 13.1.5 Key Developments 13.2 Bayer 13.2.1 Company Overview 13.2.2 Financials 13.2.3 Products 13.2.4 Strategy 13.2.5 Key Developments 13.3 Bristol-Myers Squibb 13.3.1 Company Overview 13.3.2 Financials 13.3.3 Products 13.3.4 Strategy 13.3.5 Key Developments 13.4 Ellex Medical Lasers Ltd. 13.4.1 Company Overview 13.4.2 Financials 13.4.3 Products 13.4.4 Strategy 13.4.5 Key Developments   13.5 GlaxoSmithKline plc 13.5.1 Company Overview 13.5.2 Financials 13.5.3 Products 13.5.4 Strategy 13.5.5 Key Developments 13.6 IRIDEX Corporation 13.6.1 Company Overview 13.6.2 Financials 13.6.3 Products 13.6.4 Strategy 13.6.5 Key Developments 13.7 Lumenis 13.7.1 Company Overview 13.7.2 Financials 13.7.3 Products 13.7.4 Strategy 13.7.5 Key Developments 13.8 Novartis 13.8.1 Company Overview 13.8.2 Financials 13.8.3 Products 13.8.4 Strategy 13.8.5 Key Developments 13.9 NIDEK CO.,LTD. 13.9.1 Company Overview 13.9.2 Financials 13.9.3 Products 13.9.4 Strategy 13.9.5 Key Developments 13.1 Regeneron Pharmaceuticals 13.10.1 Company Overview 13.10.2 Financials 13.10.3 Products 13.10.4 Strategy 13.10.5 Key Developments 13.11 F. Hoffmann-La Roche AG 13.11.1 Company Overview 13.11.2 Financials 13.11.3 Products 13.11.4 Strategy 13.11.5 Key Developments   13.12 Quantel Medical Inc 13.12.1 Company Overview 13.12.2 Financials 13.12.3 Products 13.12.4 Strategy 13.12.5 Key Developments 13.13 Topcon Medical Systems, Inc. 13.13.1 Company Overview 13.13.2 Financials 13.13.3 Products 13.13.4 Strategy 13.13.5 Key Developments 13.14 ZEISS 13.14.1 Company Overview 13.14.2 Financials 13.14.3 Products 13.14.4 Strategy 13.14.5 Key Developments 14 MRFR Conclusion 14.1 Key Findings 14.1.1 From CEO’s View Point 14.1.2 Unmet Needs 14.2 Key companies to watch 15 Appendix 15.1 Discussion Blue Print

List of Tables: TABLE 1 PRIMARY INTERVIEWS TABLE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR BRANCH RETINAL ARTERY OCCLUSION, BY REGION, 2014-2023 (USD MILLION) TABLE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2014-2023 (USD MILLION) TABLE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR NON-ISCHEMIC, BY REGION, 2014-2023 (USD MILLION) TABLE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ISCHEMIC, BY REGION, 2014-2023 (USD MILLION) TABLE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2014-2023 (USD MILLION) TABLE 7 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FUNDOSCOPIC EXAMINATION, BY REGION, 2014-2023 (USD MILLION) TABLE 8 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FLUORESCEIN ANGIOGRAPHY, BY REGION, 2014-2023 (USD MILLION) TABLE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2014-2023 (USD MILLION) TABLE 10 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR AFLIBERCEPT, BY REGION, 2014-2023 (USD MILLION) TABLE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RANIBIZUMAB, BY REGION, 2014-2023 (USD MILLION) TABLE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CORTICOSTEROID DRUGS, BY REGION, 2014-2023 (USD MILLION) TABLE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR TRIAMCINOLONE ACETONIDE, BY REGION, 2014-2023 (USD MILLION) TABLE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR DEXAMETHASONE, BY REGION, 2014-2023 (USD MILLION) TABLE 15 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR LASER RETINAL PHOTOCOAGULATION, BY REGION, 2014-2023 (USD MILLION) TABLE 16 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2014-2023 (USD MILLION) TABLE 17 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RESEARCH & ACADEMICS CENTERS, BY REGION, 2014-2023 (USD MILLION) TABLE 18 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY REGION, 2014-2023 (USD MILLION) TABLE 19 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 20 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 21 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 22 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 23 AMERICAS ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 24 AMERICAS CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 25 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 26 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2014-2023 (USD MILLION) TABLE 27 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 28 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 29 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 30 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 31 NORTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 32 NORTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 33 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 34 U.S. RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 35 U.S. RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 36 U.S. RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 37 U.S. RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 38 U.S. ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 39 U.S. CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 40 U.S. RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 41 CANADA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 42 CANADA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 43 CANADA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 44 CANADA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 45 CANADA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 46 CANADA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 47 CANADA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 48 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 49 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 50 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 51 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 52 SOUTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 53 SOUTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 54 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 55 EUROPE RETINAL VEIN OCCLUSION MARKET, BY REGION, 2014-2023 (USD MILLION) TABLE 56 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 57 EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 58 EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 59 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 60 EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 61 EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 62 EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 63 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2014-2023 (USD MILLION) TABLE 64 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 65 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 66 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 67 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 68 WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 69 WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 70 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 71 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 72 GERMANY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 73 GERMANY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 74 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 75 GERMANY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 76 GERMANY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 77 GERMANY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 78 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 79 FRANCE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 80 FRANCE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 81 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 82 FRANCE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 83 FRANCE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 84 FRANCE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 85 U.K RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 86 U.K RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 87 U.K RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 88 U.K RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 89 U.K ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 90 U.K CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 91 U.K RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 92 ITALY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 93 ITALY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 94 ITALY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 95 ITALY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 96 ITALY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 97 ITALY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 98 ITALY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 99 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 100 SPAIN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 101 SPAIN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 102 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 103 SPAIN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 104 SPAIN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 105 SPAIN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 106 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 107 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 108 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 109 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 110 REST OF WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 111 REST OF WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 112 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 113 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 114 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 115 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 116 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 117 EASTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 118 EASTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 119 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 120 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2014-2023 (USD MILLION) TABLE 121 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 122 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 123 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 124 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 125 ASIA PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 126 ASIA PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 127 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 128 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 129 JAPAN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 130 JAPAN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 131 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 132 JAPAN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 133 JAPAN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 134 JAPAN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 135 CHINA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 136 CHINA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 137 CHINA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 138 CHINA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 139 CHINA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 140 CHINA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 141 CHINA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 142 INDIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 143 INDIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 144 INDIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 145 INDIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 146 INDIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 147 INDIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 148 INDIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 149 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 150 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 151 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 152 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 153 AUSTRALIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 154 AUSTRALIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 155 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 156 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 157 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 158 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 159 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 160 REPUBLIC OF KOREA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 161 REPUBLIC OF KOREA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 162 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 163 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 164 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 165 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 166 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 167 REST OF ASIA PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 168 REST OF ASIA PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 169 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 170 MIDDLE EAST & AFRICA MEDICAL IMPLANTS MARKET, BY REGION, 2014-2023 (USD MILLION) TABLE 171 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 172 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 173 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, AW2014-2023 (USD MILLION) TABLE 174 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 175 MIDDLE EAST & AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 176 MIDDLE EAST & AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 177 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 178 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 179 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 180 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 181 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 182 MIDDLE EAST ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 183 MIDDLE EAST CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 184 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) TABLE 185 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 186 AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION) TABLE 187 AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) TABLE 188 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION) TABLE 189 AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 190 AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION) TABLE 191 RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION) List of Figures: FIGURE 1 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2016 (%) FIGURE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2016 (%) FIGURE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2016 (%) FIGURE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2016 (%) FIGURE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2016 (%) FIGURE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY REGION, 2016 (%) FIGURE 7 MARKET STRUCTURE OF GLOBAL RETINAL VEIN OCCLUSION MARKET FIGURE 8 RESEARCH METHODOLOGY FIGURE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET: FORECAST MODEL FIGURE 10 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2016 & 2023 (%) FIGURE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2016 & 2023 (%) FIGURE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2016 & 2023 (%) FIGURE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2016 & 2023 (%) FIGURE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2016 & 2023 (%)

Some of the key players in this market are Allergan Plc, Bayer, Bristol-Myers Squibb, Ellex Medical Lasers Ltd., GlaxoSmithKline plc, IRIDEX Corporation, Lumenis, Novartis, NIDEK CO.,LTD., Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc, Topcon Medical Systems, Inc., and ZEISS.